Edoxaban for the treatment of pediatric venous thromboembolism: phase 3 randomized controlled trial Edoxaban for the treatment of pediatric venous thromboembolism: phase 3 randomized controlled trial Jenni Thomas / Sunday, June 22, 2025 0 231 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Mihir Bhatt, M.D., M.Sc.; McMaster Children's Hospital, McMaster University; Hamilton, ON, Canada Read more
Clonal hematopoiesis of indeterminate potential in coronary disease patients: a 24-year follow-up Clonal hematopoiesis of indeterminate potential in coronary disease patients: a 24-year follow-up Jenni Thomas / Sunday, June 22, 2025 0 1204 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Cynthia Carbonneau, M.D., Ph.D.; Centre Hospitalier Universitaire de Lille; Lille, France Read more
Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura Jenni Thomas / Sunday, June 22, 2025 0 408 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Paul Coppo, M.D., Ph.D.; Saint-Antoine Hospital, Sorbonne University; Paris, France Read more
Phase 3 study of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A Phase 3 study of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A Jenni Thomas / Sunday, June 22, 2025 0 384 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Robert Sidonio, Jr., M.D., M.Sc.; Hemophilia of Georgia Center for Bleeding and Clotting Disorders of CHOA; Atlanta, GA, U.S. Read more
Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism Comparison of bleeding risk between rivaroxaban and apixaban in acute venous thromboembolism Jenni Thomas / Sunday, June 22, 2025 0 1056 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Lana Castellucci, M.D.; University of Ottawa, Ottawa Hospital; Ottawa, ON, Canada Read more